Compare VCYT & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCYT | SUPN |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2013 | 2012 |
| Metric | VCYT | SUPN |
|---|---|---|
| Price | $34.88 | $49.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $46.00 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 824.1K | 728.8K |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | $495,141,000.00 | ★ $681,539,000.00 |
| Revenue This Year | $16.72 | $8.18 |
| Revenue Next Year | $11.31 | $22.15 |
| P/E Ratio | $94.90 | ★ N/A |
| Revenue Growth | ★ 16.41 | 4.54 |
| 52 Week Low | $22.61 | $29.16 |
| 52 Week High | $50.71 | $57.65 |
| Indicator | VCYT | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 27.09 | 49.08 |
| Support Level | $40.29 | $47.29 |
| Resistance Level | $38.98 | $49.71 |
| Average True Range (ATR) | 1.84 | 1.37 |
| MACD | -0.64 | -0.14 |
| Stochastic Oscillator | 0.14 | 57.82 |
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.